Sickle Cell Disease: Targeting Alloantibody Formation Reduction; Risk Factors, and Genetics

About the study

The focus of the study is the pathophysiological mechanism of allo-antibody formation after
red blood cell transfusion in sickle cell disease patients.

Study point of contact

Karin Fijnvandraat, MD PhD
+31205123122
k.fijnvandraat@sanquin.nl

Locations

4 Netherlands sites

Study type

Observational

Gender

All

Compensation

Unknown

participation requirements

– Sickle cell disease

– Receiving a red blood cell transfusion

participation restrictions

– Previous positive screen for allo-antibodies

– >25 red blood cell units in the past

Locations

  • Amsterdam-Zuidoost, Netherlands, Academic Medical Center Amsterdam [Recruiting]
  • Den Haag, Netherlands, HagaZiekenhuis [Not yet recruiting]
  • Nijmegen, Netherlands, Radboudumc [Recruiting]
  • Rotterdam, Netherlands, Erasmus MC [Recruiting]
Last updated 2019-07-17